The abstract is read at the publisher; the summary is JClub's.
NNC0130, an orally available GLP-1R/GIPR dual agonist, produced placebo-corrected mean body weight loss of 9% after 12 weeks and 12% after 15 weeks with daily subcutaneous dosing.
- Why it matters: Oral incretin-based poly-pharmacology and oral peptide delivery are attractive, but acylated peptides often face low oral bioavailability, limiting anti-obesity efficacy.
- What they did: A panel of unimolecular, fatty-acylated GLP-1R/GIPR dual agonists was screened in cell-based receptor potency assays; NNC0130 advanced into a multiple-ascending dose trial with separate oral and subcutaneous cohorts.
- The result: Oral dosing (5–50 mg) yielded 4% placebo-corrected weight loss after 12 weeks, not statistically different from zero, while estimated relative oral bioavailability with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate was 1.6–2.2% versus subcutaneous.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.